Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA-Reference-Cited by-同舟云学术

Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA

Published:2011-05-26 Issue:18 Volume:32 Page:2282-2289
ISSN:0195-668X
Container-title:European Heart Journal
language:en
Short-container-title:European Heart Journal

Author:

Wieloch M.,Sjalander A.,Frykman V.,Rosenqvist M.,Eriksson N.,Svensson P. J.

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine

Link

http://academic.oup.com/eurheartj/article-pdf/32/18/2282/1341228/ehr134.pdf

Reference14 articles.

1. Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation

2. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation–executive summary

3. Anticoagulation Control and Prediction of Adverse Events in Patients With Atrial Fibrillation

4. Meta-Analysis to Assess the Quality of Warfarin Control in Atrial Fibrillation Patients in the United States

5. Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range

Cited by 211 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacogenomics and warfarin therapy;Therapeutic Drug Monitoring;2024

2. Which Factors Determine the Success of Anticoagulation with Warfarin;International Journal of Cardiovascular Practice;2023-10-28

3. The First Brazilian Cardiovascular Registry of Atrial Fibrillation: Primary Results of the RECALL Study;American Heart Journal;2023-10

4. Anticoagulation Control and Major Adverse Clinical Events in Patients with Operated Valvular Heart Disease with and without Atrial Fibrillation Receiving Vitamin K Antagonists;Journal of Clinical Medicine;2023-02-01

5. Resumption of anticoagulant therapy after major bleeding and the risk of negative events in patients with atrial fibrillation (based on REGistry of Long-term AnTithrombotic TherApy-2 – REGATA);Terapevticheskii arkhiv;2023-01-16